Chemours Company (CC) remains a speculative 'Buy' ahead of Q3. CC offers significant upside potential, driven by Opteon growth, market recovery, and the recent settlement of major legacy liabilities. Despite elevated leverage and earnings volatility, I see no immediate financial distress and expect improving fundamentals through 2027E.
Luminus Management LLC reduced its stake in The Chemours Company (CC -1.86%) during Q3 2025, selling shares worth an estimated $4.30 million, based on the average quarterly price, according to an SEC filing dated October 3, 2025.
Price action is one of the most important metrics to watch out for when deciding whether a potential investment setup is bullish or bearish. However, despite its importance, price action is only half the picture because relying solely on it without linking to fundamental reasons risks capital blindly.
WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (“Chemours”) today announced that its Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan to the role of Lead Independent Director, effective September 2, 2025. These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as the Chi...
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.